Article By:
KKD Healthcare Analytics
Wednesday, August 30, 2017 12:45 PM EDT
UroGen Pharma announced that the FDA has designated its MitoGel for Fast Track review for the treatment of patients with low-grade upper urinary tract urothelial carcinoma. AstraZeneca inked a new deal with Takeda Pharmaceutical.